Kintor Pharmaceutical (HKSE:09939) Total Current Assets : HK$183.35 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Kintor Pharmaceutical's total current assets for the quarter that ended in Dec. 2024 was HK$183.35 Mil.

Kintor Pharmaceutical Total Current Assets Historical Data

The historical data trend for Kintor Pharmaceutical's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Total Current Assets Chart

Kintor Pharmaceutical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

1,684.05

1,868.41

1,683.86

516.87

183.35

Kintor Pharmaceutical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Current Assets	Get a 7-Day Free Trial								1,683.86	1,464.29	516.87	399.77	183.35

Kintor Pharmaceutical Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Kintor Pharmaceutical's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	157.395	+	18.105	+	2.365	+	5.486
	=	183.35

Kintor Pharmaceutical's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	157.395	+	18.105	+	2.365	+	5.486
	=	183.35

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Kintor Pharmaceutical (HKSE:09939) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Kintor Pharmaceutical's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	157.395	-	236.005	+	0.75 * 0	+	0.5 * 2.365
=	-77.43

Kintor Pharmaceutical Total Current Assets Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintor Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

KNTPF:USA

Address

No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.kintor.com.cn

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.

Executives

Kt International Investment Limited	2101 Beneficial owner
Tong Youzhi	2201 Interest of corporation controlled by you
Tong Youzhi	2101 Beneficial owner
Guo Chuangxing	2201 Interest of corporation controlled by you
Kg Development Limited	2101 Beneficial owner
Nomura Holdings, Inc.	2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si	2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si	2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si	2101 Beneficial owner

Kintor Pharmaceutical Headlines

No Headlines